Your SlideShare is downloading. ×
0
Flamel Short Corporate 2009
Flamel Short Corporate 2009
Flamel Short Corporate 2009
Flamel Short Corporate 2009
Flamel Short Corporate 2009
Flamel Short Corporate 2009
Flamel Short Corporate 2009
Flamel Short Corporate 2009
Flamel Short Corporate 2009
Flamel Short Corporate 2009
Flamel Short Corporate 2009
Flamel Short Corporate 2009
Flamel Short Corporate 2009
Flamel Short Corporate 2009
Flamel Short Corporate 2009
Flamel Short Corporate 2009
Flamel Short Corporate 2009
Flamel Short Corporate 2009
Flamel Short Corporate 2009
Flamel Short Corporate 2009
Flamel Short Corporate 2009
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Flamel Short Corporate 2009

510

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
510
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Grégoire Franoux Licensing & Business Development franoux@flamel.com November 2009 Proprietary Information 1
  • 2. Flamel At A Glance  A Leading Drug Delivery Company.  Founded in 1990 by a team of researchers from Rhone-Poulenc Polymer Division.  Headquartered in Venissieux, France (near Lyon).  Publicly traded on Nasdaq (FLML) since 1996.  300 employees (75% in R&D and Production).  Strong commitment to science and innovation.  Solid cash position, no debt. November 2009 Proprietary Information 2
  • 3. Overview  Two innovative technology platforms: –MICROPUMP® for oral small molecule drugs and –MEDUSA® for injectable proteins and peptides  +12 Flamel products have undergone successful human clinical trials  FDA approved MICROPUMP® project with GlaxoSmithKline (GSK), for controlled release Carvedilol (Coreg CR®).  Flamel is a partnership-oriented Drug Delivery Company: Flamel’s proprietary technologies may be applied in partnership to improve new chemical entities, new proteins or currently approved drugs. November 2009 Proprietary Information 3
  • 4. Flamel’s Partners  Flamel has several ongoing MICROPUMP® partnerships including a global license and manufacturing agreement with GSK for Coreg CR®  Flamel has ongoing MEDUSA® partnerships with 8 of the TOP-25 Pharmaceutical Companies worldwide including: November 2009 Proprietary Information 4
  • 5. MICROPUMP® Technology A very performing and flexible technology for the controlled-release of small molecule drugs November 2009 Proprietary Information 5
  • 6. MICROPUMP® - Oral Delivery System for Small Molecules  The microparticles are released in the stomach and pass into the small intestine, where each microparticle releases the drug by osmotic pressure November 2009 Proprietary Information 6
  • 7. MICROPUMP® Meets Challenges for Delivery of Small Molecules  MICROPUMP® extends the release of drugs best absorbed in the small intestine (75% of all drugs)  9 molecules are proven in human clinical trials: – Lansoprazole SR – Omeprazole XL – Genvir™ (acyclovir SR) – ASACARD® (aspirin SR) Approved in Europe – Metformin XL – Augmentin SR – Coreg CR® (Carvedilol CR) Marketed by – Undisclosed cardiovascular drugs  Versatile presentation to serve all markets from pediatric to geriatric – Suspensions – Capsules – Tablets – Sachets November 2009 Proprietary Information 7
  • 8. Carvedilol Microparticules Targeted releases to prolong the release release in the stomach CR Microparticules: Once-Daily PK Profile release in the intestine C24 Carvedilol plasma concentration 0 hr 12 hr 24 hr November 2009 Proprietary Information 8
  • 9. MEDUSA® Technology An innovative biodegradable nanocarrier for the formulation and the delivery of a broad range of biotherapeutics November 2009 Proprietary Information 9
  • 10. Comparison of long-acting formulations of biologics Protein Engineering Microspheres Depot MEDUSA® (PEGylation, Albumin Fusion…) (PLA / PLGA… ) Non-immunogenic +/-   Bioactivity maintained    Fully biodegradable +/- +/-  Good local tolerance    Applicable to large and fragile Proteins    Applicable to Peptides    Simple low-cost process, easy to scale-up    Robustness / Reproducibility  +/-  Yield +/-   November 2009 Proprietary Information 10
  • 11. Rationale for a new proteins delivery system Flamel develops the Medusa Technology for the formulation and/or the sustained release of therapeutic proteins and peptides. The Technology is based on self-association of proteins or peptides with polyaminoacid nanocarriers. Unique advantages:  The biological activity is maintained: no modification of the carried therapeutic protein /peptide.  The safety profile is improved: a lower Cmax and a more regular concentration profile.  Potential improvement of therapeutic benefit.  Ability to solubilize and stabilize insoluble and/or unstable proteins/peptides and prevent their aggregation. November 2009 Proprietary Information 11
  • 12. Medusa® nanocarrier and protein adsorption Hydrophobic 20 – 40 nm Vitamin E group Hydrophobic COONa COONa nanodomain COONa COONa COONa COONa Protein or peptide Hydrophilic biodegradable poly-Glu chain Self-association of protein/peptide with Medusa nanoparticle * No chemical bond November 2009 Proprietary Information 12
  • 13. Protein XL simplified formulation process *: filtration 0.22 µm on sterile membrane Polymer solution pH, salt adjusted * 30 mg/mL Protein solution * Mixing @ 25°C Protein XL Filling Storage Protein friendly process  No organic solvent  No shear, no heat November 2009 Proprietary Information 13
  • 14. pK results in Dog: reproducibility of GMP batches (Dose 60 µg/kg IFN, SC)  IFN release extended to 6 days  Robustness of the pK profiles (5 # GMP batches made at 1 L scale, at different times and with different CROs...) November 2009 Proprietary Information 14
  • 15. Solubilization of API with Medusa [API ] Solubility of API Solubility solubilized without additive increase (mg/ml) (mg/ml) With Medusa Carvedilol 0.021-0.060 36 x 700 Simvastatine 0.013-0.050 19.2 X 1100 Nifedipine 0.010 1.8 X 180 Ketoconazole 0.010 1.2 X 120 Opioid 0.010 15 X 1500 Paclitaxel 0.001 4.8 X 4800 November 2009 Proprietary Information 15
  • 16. MEDUSA® stabilizes therapeutic proteins Example of improvement of hGH stability upon aggregation 1 2 3 4 1: 5 mg/mL hGH 2: 5 mg/mL hGH/Medusa 3: solution 1 vigorously shaken Aggregation 4: solution 2 vigorously shaken  Medusa masks hydrophobic patches of hGH.  Medusa prevents physical aggregation of hGH. November 2009 Proprietary Information 16
  • 17. Solubilization of protein (IL-2) using Medusa® IL-2 with an isoelectric point 6.8 is insoluble at neutral pH. IL-2 at pH 7.2:  INSOLUBLE (solubility < 0.3 mg/ml) IL-2/HMpGlu at pH 7.2:  SOLUBLE up to 10 mg/ml  Medusa improves the IL-2 solubility (loading up to 50% wt/wt) while preserving the full bio-activity of the protein. November 2009 Proprietary Information 17
  • 18. IL-2 XL: pK response in human versus Proleukin 6000 Medusil (Il-2-XL) Proleukin 5000 •Treatment A : 10.6*106IU/m2 Proleukin seric Il-2 concentration (pg/ml) 4000 •Treatment B : 10.6*106IU/m2 IL-2 XL 3000 2000 1000 0 0 1 2 3 4 5 6 7 8 times (days) Sustained release of IL-2 demonstrated (decrease of Cmax (2.4 fold); increase of Tmax). In addition, AUC is also increased ( +60%). The pharmacokinetic profile supports the once a week administration November 2009 Proprietary Information 18
  • 19. Medusa: a wide range of applications Peptides Insulin, PYY, GLP-1, Immuno- ≤7 peptides… Medium-sized Proteins 7≤X≤100 Hormones (hGH…) , Cytokines (IFNs, interleukins…), Fab’, Antigens… Large Proteins ≥100 Enzymes, Antibodies, Blood coagulation factors… KDa November 2009 Proprietary Information 19
  • 20. Pessac Development and Manufacturing Facility AFSSAPS (French Agency), FDA approved site November 2009 Proprietary Information 20
  • 21. Flamel, a unique and successful drug delivery company with:  One successful product on the market, validating Flamel’s know-how and technologies (GSK’s Coreg CR)  More than 15 ongoing innovative formulation projects financed by different pharmaceutical partners  Breakthrough technologies for the formulation and the delivery of the next-generation of biotherapeutics  A world-class team of polymer and formulation researchers with unsurpassed experience in the drug delivery field  Significant and growing intellectual property portfolio (more than 60 patent families)  An FDA/Affsaps approved pharmaceutical plant for scale-up and commercial manufacturing  A very solid financial position  A nimble approach to collaboration structures with pharmaceutical and biotech companies November 2009 Proprietary Information 21

×